Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Stefanski

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Transplantation and Cellular Therapy|June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryRachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
The New England Journal of Medicine|February 1, 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L Maude, Theodore W Laetsch, Jochen Buechner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Transplantation and Cellular Therapy|June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryRachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
The New England Journal of Medicine|February 1, 2018
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L Maude, Theodore W Laetsch, Jochen Buechner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Pageof 11